2022
The Impact of Mental Health Intensive Case Management on Functioning and Clinical Outcomes of Older Black and White Veterans With Serious Mental Illness
Browne J, Mohamed S. The Impact of Mental Health Intensive Case Management on Functioning and Clinical Outcomes of Older Black and White Veterans With Serious Mental Illness. American Journal Of Geriatric Psychiatry 2022, 30: 1183-1194. PMID: 35365385, DOI: 10.1016/j.jagp.2022.02.009.Peer-Reviewed Original ResearchConceptsSerious mental illnessIntensive case managementAnxiety/depressionClinical outcomesWhite veteransBlack veteransUse disordersMental illnessMental health recovery programsCase managementNational program evaluation dataDrug use disordersVeterans Health Administration programHigh-intensity servicesAlcohol use disorderSubstance use treatmentWhite older adultsGreater improvementService deliveryMedication managementBaseline differencesOutcome measuresSociodemographic factorsEqual-access settingSecondary analysis
2019
General Predictors and Moderators of Depression Remission: A VAST-D Report
Zisook S, Johnson GR, Tal I, Hicks P, Chen P, Davis L, Thase M, Zhao Y, Vertrees J, Mohamed S. General Predictors and Moderators of Depression Remission: A VAST-D Report. American Journal Of Psychiatry 2019, 176: 348-357. PMID: 30947531, DOI: 10.1176/appi.ajp.2018.18091079.Peer-Reviewed Original ResearchMeSH KeywordsAdultAdverse Childhood ExperiencesAgedAged, 80 and overAntidepressive AgentsAripiprazoleBupropionDepressive Disorder, MajorDrug SubstitutionDrug Therapy, CombinationEmploymentFemaleGriefHumansLife TablesMaleMiddle AgedPrognosisQuality of LifeRemission InductionSeverity of Illness IndexSingle-Blind MethodUnited StatesUnited States Department of Veterans AffairsYoung AdultConceptsNext-step treatmentsRelease bupropionVeterans Health Administration patientsPatients' baseline featuresSingle-blind trialMajor depressive disorderDepression Outcomes studyComplicated grief symptomsAntidepressant treatmentBaseline characteristicsInitial treatmentDepression remissionDepressive disorderRemissionOutcome studiesTreatment selectionTreatment groupsHypomanic symptomsSwitching treatmentClinical imperativePositive mental healthChildhood adversityPatientsMental healthSpecific augmentation
2018
Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial.
Yoon J, Zisook S, Park A, Johnson GR, Scrymgeour A, Mohamed S. Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial. The Journal Of Clinical Psychiatry 2018, 80 PMID: 30695291, DOI: 10.4088/jcp.18m12294.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntidepressive Agents, Second-GenerationAripiprazoleBupropionCost-Benefit AnalysisDepressionDepressive Disorder, MajorDrug SubstitutionDrug SynergismDrug Therapy, CombinationFemaleHumansMaleMiddle AgedOutcome Assessment, Health CareRemission InductionUnited StatesUnited States Department of Veterans AffairsVeteransConceptsIncremental cost-effectiveness ratioStandard antidepressant therapyBupropion augmentationAripiprazole augmentationAntidepressant therapyClinical trialsVeterans Affairs Medical CenterDepression Outcomes trialMental health care costsRate of remissionRandomized clinical trialsHealth care sector perspectiveICD-9 codesTreatment of depressionCost-effectiveness ratioHealth care costsCost-effective relativeCost-effectiveness analysisOutcome trialsMean ageQuick InventoryDepression diagnosisTreatment strategiesRemissionMedical Center
2016
Comparison of burden among family members of patients diagnosed with schizophrenia and bipolar disorder in a large acute psychiatric hospital in China
Zhou Y, Rosenheck R, Mohamed S, Ou Y, Ning Y, He H. Comparison of burden among family members of patients diagnosed with schizophrenia and bipolar disorder in a large acute psychiatric hospital in China. BMC Psychiatry 2016, 16: 283. PMID: 27515535, PMCID: PMC4980784, DOI: 10.1186/s12888-016-0962-y.Peer-Reviewed Original ResearchConceptsFamily burdenBipolar disorderPsychiatric hospitalDifference of burdenWeeks of patientsMethodsTwo hundred fortyCross-sectional studyFamilies of patientsAcute psychiatric hospitalLarge psychiatric hospitalBipolar disorder patientsQuality of lifeComparison of burdenClinical featuresAcute patientsPredictive factorsCaregiver burdenHundred fortyDisorder patientsSchizophrenic patientsBipolar patientsPatientsSchizophrenia patientsSuicidal riskCaregivers' perceptionsCharacteristics of U.S. Veteran Patients with Major Depressive Disorder who require “next-step” treatments: A VAST-D report
Zisook S, Tal I, Weingart K, Hicks P, Davis LL, Chen P, Yoon J, Johnson GR, Vertrees JE, Rao S, Pilkinton PD, Wilcox JA, Sapra M, Iranmanesh A, Huang GD, Mohamed S. Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require “next-step” treatments: A VAST-D report. Journal Of Affective Disorders 2016, 206: 232-240. PMID: 27479536, DOI: 10.1016/j.jad.2016.07.023.Peer-Reviewed Original ResearchConceptsMajor depressive disorderClinical featuresDepressive disorderNonpsychotic major depressive disorderInitial standard treatmentNon-veteran samplesU.S. veteran patientsCharacteristics of patientsSample of veteransRecent suicidal ideationPublic health imperativeLasting treatmentMDD treatmentVeteran patientsClinical onsetPsychiatric comorbidityAntidepressant trialsStandard treatmentClinical trialsDepression subtypesRecurrent depressionIndividual patientsSpecific treatmentPatientsSuicidal ideation
2015
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia
Mohamed S, Rosenheck RA, Lin H, Swartz M, McEvoy J, Stroup S. Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. The Journal Of Nervous And Mental Disease 2015, 203: 486-492. PMID: 26075840, DOI: 10.1097/nmd.0000000000000317.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlcoholismAntipsychotic AgentsBenzodiazepinesChronic DiseaseComorbidityCross-Sectional StudiesDibenzothiazepinesDouble-Blind MethodFemaleHumansIllicit DrugsMaleMiddle AgedOlanzapinePerphenazinePiperazinesPsychiatric Status Rating ScalesQuetiapine FumarateRisperidoneSchizophreniaSchizophrenic PsychologySmokingSmoking PreventionSubstance-Related DisordersThiazolesYoung AdultConceptsSecond-generation antipsychotic drugsAntipsychotic drugsFirst-generation antipsychoticsSecond-generation antipsychoticsIntervention Effectiveness (CATIE) studySecondary outcome dataClinical Antipsychotic TrialsFirst-generation drugsSubstance use outcomesCigarette smokingSchizophrenia trialsChronic schizophreniaAntipsychotic TrialsOutcome dataNicotine useDrug useSecondary analysisPast weekAntipsychoticsEffectiveness studiesPatientsSubstance useUse outcomesTrialsDrugs
2011
Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease.
Mohamed S, Rosenheck R, Lyketsos CG, Kaczynski R, Sultzer DL, Schneider LS. Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease. The Journal Of Clinical Psychiatry 2011, 73: 121-8. PMID: 21939611, PMCID: PMC4040971, DOI: 10.4088/jcp.10m06574.Peer-Reviewed Original ResearchConceptsCaregiver Distress ScaleCaregivers of patientsSecond-generation antipsychoticsCaregiver burdenExperiences of caregiversAlzheimer's diseaseBurden InterviewDisease trialsNeuropsychiatric Inventory Caregiver Distress ScaleDistress ScaleCATIE-AD trialAtypical antipsychotic treatmentUsual care settingsAtypical antipsychotic drugsClinical Antipsychotic TrialsSymptoms of psychosisBeck Depression InventoryAD outpatientsTreat analysisAtypical antipsychoticsAntipsychotic treatmentAD patientsAntipsychotic drugsAntipsychotic TrialsCare settings
2010
Caregiver Burden in Alzheimer Disease: Cross-Sectional and Longitudinal Patient Correlates
Mohamed S, Rosenheck R, Lyketsos CG, Schneider LS. Caregiver Burden in Alzheimer Disease: Cross-Sectional and Longitudinal Patient Correlates. American Journal Of Geriatric Psychiatry 2010, 18: 917-927. PMID: 20808108, PMCID: PMC3972419, DOI: 10.1097/jgp.0b013e3181d5745d.Peer-Reviewed Original ResearchConceptsAlzheimer's diseasePatients' qualityCaregiver burdenCognitive statusCaregiver Distress ScaleUsual care settingsIntensity of careLower functional capabilitySix-month changesClinical Antipsychotic TrialsProbable Alzheimer's diseasePatients' cognitive statusDiagnosis of dementiaQuality of lifeBeck Depression InventoryCATIE-ADRelationship of burdenBurden InterviewAmbulatory outpatientsPatients CorrelatePharmacologic interventionsAntipsychotic TrialsTreatment outcomesDecreased burdenCare settingsImpact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.
Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, Swartz MS, Lieberman JA. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. The Journal Of Clinical Psychiatry 2010, 72: 75-80. PMID: 20868641, PMCID: PMC5052810, DOI: 10.4088/jcp.09m05258gre.Peer-Reviewed Original ResearchConceptsMajor depressive episodeSecond-generation antipsychoticsDSM-IV-defined schizophreniaCurrent major depressive episodeClinical practice recommendationsTrial of treatmentClinical practice guidelinesTreatment of depressionCalgary Depression ScaleClinical Antipsychotic TrialsSecond-generation drugsSymptoms of depressionPhase 1 analysisTardive dyskinesiaDepressive episodeChronic schizophreniaAntipsychotic TrialsPractice guidelinesDepression ScaleDepressive symptomsTreatment groupsBaseline scoresPatientsAntipsychoticsPractice recommendationsAugmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial.
Zisook S, Kasckow JW, Lanouette NM, Golshan S, Fellows I, Vahia I, Mohamed S, Rao S. Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial. The Journal Of Clinical Psychiatry 2010, 71: 915-22. PMID: 20361918, DOI: 10.4088/jcp.09m05699gre.Peer-Reviewed Original ResearchConceptsBaseline suicidal ideationHamilton Depression Rating ScaleDepression Rating ScaleSubthreshold depressive symptomsCalgary Depression Rating ScaleDepressive symptomsSuicidal ideationSchizoaffective disorderClinical Global Impressions-SeverityBeck Hopelessness ScaleDSM-IV-diagnosed schizophreniaRating ScaleTreatment-emergent suicidal ideationPlacebo-controlled trialSuicidal ideation measuresItem 3Citalopram augmentationFinal visitPlacebo augmentationSecondary outcomesPrimary outcomeOlder outpatientsInterSePT ScaleCitalopramPlacebo
2009
Off-Label Use of Antipsychotic Medications in the Department of Veterans Affairs Health Care System
Leslie DL, Mohamed S, Rosenheck RA. Off-Label Use of Antipsychotic Medications in the Department of Veterans Affairs Health Care System. Psychiatric Services 2009, 60: 1175-1181. PMID: 19723731, DOI: 10.1176/ps.2009.60.9.1175.Peer-Reviewed Original ResearchConceptsAntipsychotic medicationLabel useLogistic regression modelsBipolar disorderVeterans Affairs Health Care SystemVeterans AffairsMultivariate logistic regression modelVA administrative databasesHalf of patientsFirst-generation antipsychoticsOff-label useSevere side effectsMental illness diagnosisPosttraumatic stress disorderHealth care systemClinical characteristicsRegression modelsAntipsychotic useVA patientsAdministrative databasesMinor depressionMajor depressionHigher oddsMedicationsSide effectsVeterans Affairs Intensive Case Management for Older Veterans
Mohamed S, Neale MS, Rosenheck R. Veterans Affairs Intensive Case Management for Older Veterans. American Journal Of Geriatric Psychiatry 2009, 17: 671-681. PMID: 19625784, DOI: 10.1097/jgp.0b013e3181a88340.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionAgedAged, 80 and overCase ManagementCommunity Mental Health ServicesEvidence-Based PracticeFemaleHealth Services AccessibilityHumansLength of StayMaleMental DisordersMiddle AgedPsychiatric Status Rating ScalesSurveys and QuestionnairesTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsVeteransConceptsSevere mental illnessAssertive community treatmentOlder veteransIntensive case management programComorbid substance abuseNursing home placementIntensive case managementLate-onset problemsCase management programCommunity-based servicesRecovery-oriented servicesNonpsychotic illnessesYounger patientsEvidence-based practiceHospital treatmentElderly veteransTreatment outcomesFamily burdenCommunity treatmentRespite servicesMental illnessRecovery-focused servicesCase managementSubstance abuseElderly peopleUse of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs.
Mohamed S, Leslie DL, Rosenheck RA. Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs. The Journal Of Clinical Psychiatry 2009, 70: 906-12. PMID: 19422760, DOI: 10.4088/jcp.08m04450.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overAntidepressive AgentsAntipsychotic AgentsComorbidityDepressive Disorder, MajorDose-Response Relationship, DrugDrug Therapy, CombinationDrug UtilizationFemaleHospitals, VeteransHumansMaleMiddle AgedUnited StatesUnited States Food and Drug AdministrationVeteransConceptsMajor depressive disorderTreatment of MDDAntipsychotic medicationDepressive disorderService useMental health service useVeterans Affairs patientsUse of antipsychoticsHealth service useComorbid mental illnessDrug Administration approvalLong-term safetyRecent U.S. FoodFirst antipsychoticAntipsychotic dosesAntipsychotic prescriptionsPsychiatric comorbidityComorbid schizophreniaMale genderAdministration approvalVeteran characteristicsMedicationsSchizoaffective disorderAntipsychoticsBipolar disorder
2008
Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial.
Zisook S, Kasckow JW, Golshan S, Fellows I, Solorzano E, Lehman D, Mohamed S, Jeste DV. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. The Journal Of Clinical Psychiatry 2008, 70: 562-71. PMID: 19192468, DOI: 10.4088/jcp.08m04261.Peer-Reviewed Original ResearchConceptsQuality of lifeSubsyndromal symptomsSchizoaffective disorderOlder patientsOlder outpatientsTreatment groupsRandomized placebo-controlled trialRating ScaleFlexible-dose treatmentSecondary efficacy analysesPlacebo-controlled trialCurrent antipsychotic medicationsDepression Rating ScaleGeneral medical healthHamilton Rating ScaleCalgary Depression Rating ScaleYears of ageDSM-IV schizophreniaCitalopram augmentationAdverse eventsPlacebo augmentationEfficacy analysisAntipsychotic medicationStudy criteriaDimensions of schizophreniaPharmacotherapy for Older Veterans Diagnosed With Posttraumatic Stress Disorder in Veterans Administration
Mohamed S, Rosenheck R. Pharmacotherapy for Older Veterans Diagnosed With Posttraumatic Stress Disorder in Veterans Administration. American Journal Of Geriatric Psychiatry 2008, 16: 804-812. PMID: 18827226, DOI: 10.1097/jgp.0b013e318173f617.Peer-Reviewed Original ResearchConceptsMental health clinicsSpecialty mental health clinicsPosttraumatic stress disorderOlder veteransHealth clinicsVeterans AdministrationPsychotropic medicationsPharmacotherapy of PTSDStress disorderDegree of undertreatmentPsychotropic medication classesMultivariable logistic regressionUse of medicationsYears of ageRelationship of ageMedication classesMedication utilizationPatients 45Medication usePsychotropic prescriptionsClinic typePrimary careElderly veteransSedative hypnoticsVA servicesCross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia
Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia. Schizophrenia Bulletin 2008, 35: 336-346. PMID: 18586692, PMCID: PMC2659303, DOI: 10.1093/schbul/sbn067.Peer-Reviewed Original ResearchConceptsPositive medication attitudesMedication attitudesSymptoms of schizophreniaSchizophrenia symptomsGreater medication complianceDrug Attitude InventoryRelationship of insightClinical Antipsychotic TrialsTreatment Attitudes QuestionnaireGreater patient understandingLevel of depressionMixed model regression analysisLower symptom levelsRecovery-oriented servicesClinical outcomesMedication adherenceMedication complianceChronic schizophreniaAntipsychotic TrialsPatient understandingModel regression analysisMedicationsCommunity functioningPsychosocial rehabilitationSymptomsRelationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia
Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RS. Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia. American Journal Of Psychiatry 2008, 165: 978-987. PMID: 18450928, DOI: 10.1176/appi.ajp.2008.07111713.Peer-Reviewed Original ResearchInsight, quality of life, and functional capacity in middle‐aged and older adults with schizophrenia
Roseman AS, Kasckow J, Fellows I, Osatuke K, Patterson TL, Mohamed S, Zisook S. Insight, quality of life, and functional capacity in middle‐aged and older adults with schizophrenia. International Journal Of Geriatric Psychiatry 2008, 23: 760-765. PMID: 18205246, PMCID: PMC3428424, DOI: 10.1002/gps.1978.Peer-Reviewed Original Research
2007
Suicidality in middle aged and older patients with schizophrenia and depressive symptoms: relationship to functioning and Quality of Life
Kasckow J, Montross L, Golshan S, Mohamed S, Patterson T, Sollanzano E, Zisook S. Suicidality in middle aged and older patients with schizophrenia and depressive symptoms: relationship to functioning and Quality of Life. International Journal Of Geriatric Psychiatry 2007, 22: 1223-1228. PMID: 17506025, PMCID: PMC3118557, DOI: 10.1002/gps.1817.Peer-Reviewed Original ResearchConceptsQuality of lifeMedication Management Ability AssessmentDepressive symptomsQLS scoresUCSD Performance-based Skills AssessmentOlder patientsSocial Skills Performance AssessmentLeast mild degreeDSM-IV criteriaMore depressive symptomsWorse qualityMean ageISS scoreMedication managementMajor depressionMild degreeHeinrichs QualitySchizoaffective disorderPatientsPerformance-Based Skills AssessmentSignificant associationSpearman's rho correlational analysisWorse functioning
2006
Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial
Mohamed S, Osatuke K, Aslam M, Kasckow J. Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial. The American Journal Of Geriatric Pharmacotherapy 2006, 4: 201-209. PMID: 17062320, DOI: 10.1016/j.amjopharm.2006.08.001.Peer-Reviewed Original ResearchConceptsMajor depressive disorderComorbid major depressive disorderElderly patientsComorbid depressionEscitalopram 10Adverse eventsPilot trialBaseline Montgomery-Asberg Depression Rating Scale (MADRS) scoreMontgomery-Asberg Depression Rating Scale scoreSecondary efficacy end pointsSelective serotonin reuptake inhibitorsDepression Rating Scale scoresVeterans Affairs Medical CenterEfficacy end pointPrimary efficacy variableMedical Outcomes StudySerotonin reuptake inhibitorsShort-term administrationHAM-A scoresHamilton Rating ScaleLack of efficacyPoor treatment responseRating Scale scoresSymptoms of depressionGreater symptom severity